{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:24:54Z","timestamp":1762100694212,"version":"3.33.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,9,6]],"date-time":"2007-09-06T00:00:00Z","timestamp":1189036800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2008,1]]},"DOI":"10.1007\/s00296-007-0436-0","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T23:47:58Z","timestamp":1188949678000},"page":"261-269","source":"Crossref","is-referenced-by-count":18,"title":["Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment"],"prefix":"10.1007","volume":"28","author":[{"given":"Tiina","family":"Lev\u00e4lampi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Korpela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katriina","family":"Vuolteenaho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eeva","family":"Moilanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,9,6]]},"reference":[{"key":"436_CR1","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME (1999) Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130:478\u2013486","journal-title":"Ann Intern Med"},{"key":"436_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35\u201345","journal-title":"Arthritis Rheum"},{"key":"436_CR3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)15640-7","volume":"363","author":"L Klareskog","year":"2004","unstructured":"Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (trial of etanercept, methotrexate with radiographic patient outcomes) study investigators (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363:675\u2013681","journal-title":"Lancet"},{"key":"436_CR4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1136\/ard.2003.013052","volume":"63","author":"LB Putte van de","year":"2004","unstructured":"van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H (2004) Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 63:508\u2013516","journal-title":"Ann Rheum Dis"},{"key":"436_CR5","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/03009740510026599","volume":"34","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Brandt J, Sieper J (2005) Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34:178\u2013190","journal-title":"Scand J Rheumatol"},{"key":"436_CR6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KL Hyrich","year":"2007","unstructured":"Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, British society for rheumatology biologics register (2007) Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 56:13\u201320","journal-title":"Arthritis Rheum"},{"key":"436_CR7","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","volume":"52","author":"J Listing","year":"2005","unstructured":"Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52:3403\u20133412","journal-title":"Arthritis Rheum"},{"key":"436_CR8","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"WG Dixon","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP, British society for rheumatology biologics register (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368\u20132376","journal-title":"Arthritis Rheum"},{"key":"436_CR9","doi-asserted-by":"crossref","unstructured":"Salliot C, Gossec L, Ruyssen-Witrand A, Luc M, Duclos M, Guignard S, Dougados M (2006) Infections during tumour necrosis factor-{alpha} blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford)","DOI":"10.1093\/rheumatology\/kel236"},{"key":"436_CR10","unstructured":"Working group set by Finnish Medical Society Duodecim and Finnish Society for Rheumatology, Helsinki, Finland. (Updated 08.06.2003) Rheumatoid arthritis Current Care Guideline. Finnish Medical Society Duodecim. Available at http:\/\/www.kaypahoito.fi (in Finnish)"},{"key":"436_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"key":"436_CR12","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","volume":"353","author":"T Mottonen","year":"1999","unstructured":"Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Jarvinen P, Hakola M, Piirainen H, Ahonen J, Palvimaki I, Forsberg S, Koota K, Friman C (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353:1568\u20131573","journal-title":"Lancet"},{"key":"436_CR13","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard.2004.023473","volume":"64","author":"N Feltelius","year":"2005","unstructured":"Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L, ARTIS Group (2005) Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64:246\u2013252","journal-title":"Ann Rheum Dis"},{"key":"436_CR14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jbspin.2006.06.011","volume":"74","author":"O Brocq","year":"2007","unstructured":"Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, Mousnier A, Euller-Ziegler L (2007) TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 74:148\u2013154","journal-title":"Joint Bone Spine"},{"key":"436_CR15","doi-asserted-by":"crossref","first-page":"R174","DOI":"10.1186\/ar2084","volume":"8","author":"LE Kristensen","year":"2006","unstructured":"Kristensen LE, Saxne T, Nilsson JA, Geborek P (2006) Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 8:R174","journal-title":"Arthritis Res Ther"},{"key":"436_CR16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26\u201337","journal-title":"Arthritis Rheum"},{"issue":"Suppl2","key":"436_CR17","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.62.suppl_2.ii30","volume":"62","author":"M Flendrie","year":"2003","unstructured":"Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL (2003) Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 62(Suppl2):ii30\u2013ii33","journal-title":"Ann Rheum Dis"},{"key":"436_CR18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1136\/ard.2004.031476","volume":"64","author":"A Zink","year":"2005","unstructured":"Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274\u20131279","journal-title":"Ann Rheum Dis"},{"key":"436_CR19","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, Gomez-Reino JJ, BIOBADASER Group (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 8:R72","journal-title":"Arthritis Res Ther"},{"key":"436_CR20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1136\/bmj.290.6484.1797","volume":"290","author":"O Mutru","year":"1985","unstructured":"Mutru O, Laakso M, Isomaki H, Koota K (1985) Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 290:1797\u20131799","journal-title":"Br Med J (Clin Res Ed)"},{"key":"436_CR21","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","volume":"46","author":"MF Doran","year":"2002","unstructured":"Doran MF, Crowson CS, Pond GR, O\u2019Fallon WM, Gabriel SE (2002) Predictors of infection in rheumatoid arthritis. Arthritis Rheum 46:2294\u20132300","journal-title":"Arthritis Rheum"},{"key":"436_CR22","first-page":"10","volume":"62","author":"HA Capell","year":"2001","unstructured":"Capell HA (2001) Disease modifying antirheumatic drugs: longterm safety issues. J Rheumatol Suppl 62:10\u201315","journal-title":"J Rheumatol Suppl"},{"key":"436_CR23","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418\u2013426","journal-title":"J Pharmacol Exp Ther"},{"key":"436_CR24","first-page":"13","volume":"74","author":"I Nestorov","year":"2005","unstructured":"Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13\u201318","journal-title":"J Rheumatol Suppl"},{"key":"436_CR25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.semarthrit.2006.02.001","volume":"36","author":"DE Furst","year":"2006","unstructured":"Furst DE, Wallis R, Broder M, Beenhouwer DO (2006) Tumor necrosis factor antagonists: different kinetics and\/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 36:159\u2013167","journal-title":"Semin Arthritis Rheum"},{"key":"436_CR26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43:717\u2013722","journal-title":"Clin Infect Dis"},{"key":"436_CR27","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/kel227","volume":"45","author":"AW Rijthoven van","year":"2006","unstructured":"van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA (2006) Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology 45:1317\u20131319","journal-title":"Rheumatology"},{"key":"436_CR28","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s00296-005-0097-9","volume":"26","author":"L Konttinen","year":"2006","unstructured":"Konttinen L, Honkanen V, Uotila T, Pollanen J, Waahtera M, Romu M, Puolakka K, Vasala M, Karjalainen A, Luukkainen R, Nordstrom DC, for the ROB-FIN study group (2006) Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events. Rheumatol Int 26:916\u2013922","journal-title":"Rheumatol Int"},{"key":"436_CR29","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"KL Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons DP (2004) Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538\u20131543","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0436-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-007-0436-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-007-0436-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T21:02:00Z","timestamp":1737406920000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-007-0436-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s00296-007-0436-0","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2007,9,6]]}}}